Clinical Trial Search

Primary: Percentage of Subjects With Serum Potassium in the Target Range (3.8 - 5.0 mEq/L) at Either Week 3 or Week 4 — 82.5; 87.3 percentage of participants

Primary: Complication Free Rate — 97.5 percentage of patients without event

Primary: Percentage of Participants With Headache Relief at 60 Minutes Post Dose(Migraine) or 30 Minutes Post Dose(Cluster Headache) — 93.9; 93.9; 93.9 Percentage of participants

Primary: Functional Independence Measure (FIM) — 20.1; 10 units on a scale — p=.015

Primary: Percentage of Participants Who Have an Investigator Global Assessment (IGA) Score of Clear or Almost Clear (0 or 1) at Week 12 and a Minimum 2 Grade Improvement in IGA…

Primary: Confirmed Best Overall Response Rate (BORR) — 37.1; 50.0; 0; 7.4 percentage of participants

Primary: Number of Hips Requiring Revision or Pending Revision of the Acetabular Shell (as Defined by Radiographic Parameters) Due to Instability or Lack of Fixation — 4 hips

Primary: Number of Participants With the Ability to Successfully Taper Prednisone to a Dose Lower Dose. — 14 Participants

Primary: Time to Clinical Response (TTCR) in Participants With Confirmed Influenza — 5.87; 5.14; 5.63 Days — p=0.25

Primary: Number of Participants Who Self-report Abstinence From Tobacco — 144; 65 Participants

Primary: T Cell Responses Following Immunization — 1.5; 1.7; 1.9; 1.6 fold change

Primary: Change From Baseline in the Ocular Surface Disease Index© (OSDI©) Score — 41.12; 39.63; -15.61; -13.16 score on a scale

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 100.0; 100.0 percentage of participants

Primary: Changes in Internal Carotid Artery Blood Flow by Treatment of Anaesthesia-induced Hypotension — 27 ml/min — p=0.0276

Primary: Number of Participants With Major Adverse Cardiovascular Events (MACE) — 0; 0; 2; 1 Participants